Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1443-1451

  Montero Julian, Félix A ^a   Brailly, Hervé ^a   Sautès, Catherine ^b   Joyeux, Isabelle ^b   Dorval, Thierry ^b   Mosseri, Véronique ^b   Yasukawa, Kiyoshi ^c   Wijdenes, John ^d   Adler, Aliza ^e   Gorin, Isabelle ^b   Fridman, Wolf H ^b   Tartour, Eric ^b  

^a Immunotech   (France)

^b INSTITUT CURIE   (France)

^c TOSOH CORPORATION   (Japan)

^d Innotest   (France)

^e RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; ONCOSTATIN M;

ARTICLE; CANCER CELL CULTURE; DEGLYCOSYLATION; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; ANTIGENS, CD; CILIARY NEUROTROPHIC FACTOR; CYTOKINE RECEPTOR GP130; CYTOKINES; FEMALE; GROWTH INHIBITORS; HUMANS; INTERLEUKIN-11; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOKINES; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; NERVE TISSUE PROTEINS; ONCOSTATIN M; PEPTIDES; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030855148     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kishimoto, T., Akira, S., Narazaki, M., and Taga, T. Interleukin-6 family of cytokines and gp130. Blood, 86: 1243-1254, 1995.
2. Baumann, H., and Gauldie, J. The acute phase response. Immunol. Today, 15: 74-80, 1994.
3. Espat, N. J., Auffenberg, T., Rosenberg, J. J., Rogy, M., Martin, D., Fang, C. H., Hasselgren, P. O, Copeland, E. M., and Moldawer, L. L. Ciliary neurotrophic factor is catabolic and shares with IL6 the capacity to induce an acute phase response. Am. J. Physiol., 271: 185-190, 1996.
4. Bruce, A. G., Hoggatt, I. H., and Rose, T. M. Oncostatin M is a differentiation factor for myeloid leukemia cells. J. Immunol., 149: 1271-1275, 1992.
5. Liu, J., Shoyab, M., and Grove, R. I. Induction of EGR-1 by oncostatin M precedes upregulation of LDL receptor in HepG2 cells. Cell Growth & Differ., 4: 611-616, 1993.
6. Davis, S., Aldrich, T. H., Ip, N. Y., Stahl, N., Scherer, S., Farruggella, T., DiStefano, P. S., Curtis, R., Panayotatos, N., Gascan, H., Chevalier, S., and Yancopoulos, G. D. Released form of CNTF receptor a component as a soluble mediator of CNTF responses. Science (Washington DC), 259: 1736-1739, 1993.
7. Heymann, D., Harb, J., Ringeard, S., Blanchard, F., Lassort, D., Raher, S., and Godard, A. Upmodulation of α v β 1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: correlation with increased cell adhesion on fibronectin. J. Cell Biochem., 58: 305-314, 1995.
8. Tamm, I., Cardinale, I., Krueger, J., Murphy, J. S., May, L. T., and Sehgal, P. B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med., 170: 1649-1669, 1989.
9. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83-85, 1988.
10. Miki, S., Iswano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 250: 607-610, 1989.
11. Eustace, D., Han, X., Gooding, R., Rowbottom, A., Riches, P., and Heyderman, E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol. Oncol., 50: 15-19, 1993.
12. Miles, S. A., Rezai, A. R., Salazar, J. F., Meyden, M. V., Stevens, R. H., Logan, D. M., Mitsuyasu, R. T., Taga, T., Hirano, Y., Kishimoto, T., and Martinez-Maza, O. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin-6. Proc. Natl. Acad. Sci. USA, 87: 4068-4072, 1990.
13. Kellokumu-Lehtinen, P., Talpaz, M., Harris, D., Van, Q., Kurzrock, R., and Estrov, Z., Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cells. Int. J. Cancer, 66: 515-519, 1996.
14. Miles, S. A., Martinez-Maza, O., Rezai, A., Magpantay, L., Kishimoto, T., Nakamura, S., Radka, S. F., and Linsley, P. S. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science (Washington DC), 255: 1432-1434, 1992.
15. Murakami-Mori, K., Taga, T., Kishimoto, T., and Nakamura, S. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. J. Clin. Invest., 96: 1319-1327, 1995.
16. Kobayashi, S., Teramura, M., Sugawara, I., Oshimi, K., and Mizoguchi, H. Interleukin 11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood, 81: 889-893, 1993.
17. Nishimoto, N., Ogata, A., Shima, Y., Tani, Y., Ogawa, H., Nakagawa, M., Sugiyama, Y., Yoshizaki, K., and Kishimoto, T. Oncostatin M, leukemia inhibitory factor and interleukin 6 induce the proliferation of human plasmocytoma cells via the common signal transducer, gp130. J. Exp. Med., 179: 1343-1347, 1994.
18. Zhang, X. G., Gu, J. J., Lu, Z. Y., Yasukawa, K., Yancopoulos, G. D., Turner, K., Shoyab, M., Taga, T., Kishimoto, T., Bataille, R., and Klein, B. Ciliary neurotrophic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J. Exp. Med., 177: 1337-1342, 1994.
19. Lu, C., Vickers, M. F., and Kerbel, R. S. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Natl. Acad. Sci. USA, 89: 9215-9219, 1992.
20. Lu, C., Rak, J. W., Kobayashi, H., and Kerbel, R. S. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced stage lesions. Cancer Res., 53: 2708-2711, 1993.
21. Vink, A., Coulie, P., Warnier, G., Renauld, J. C., Stevens, M., Donckers, D., and Van Snick, J. Mouse plasmocytoma growth in vivo: enhancement by interleukin 6 (IL6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med., 172: 997-1000, 1990.
22. Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T., and Kishimoto, T. Anti-human interleukin 6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol., 22: 1989-1993, 1993.
23. Klein, B., Wijdenes, J., Zhang, X. G., Jourdan, M., Boiron, J. M., Brochier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fournier, B., Lu, Z. Y., Mannoni, P., Sany, J., and Bataille, R. Murine anti-interleukin-6 monoclonal antibody therapy for patient with plasma cell leukemia. Blood, 78: 1198-1204, 1993.
24. Layton, M. J., Cross, B. A., Metcalf, D., Ward, L. D., Simpson, R. J., and Nicola, N. A. A major binding protein for leukemia inhibitory factor in normal mouse serum: identification as a soluble form of the cellular receptor. Proc. Natl. Acad. Sci. USA, 89: 8616-8620, 1992.
25. Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., and Kishimoto, T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58: 573-581, 1989.
26. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., and Kishimoto, T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell, 63: 1149-1157, 1990.
27. Peters, M., Jacobs, S., Ehlers, M., Vollmer, P., Mullberg, J., Wolf, E., Brem, G., Meyer zum Buschenfelde, K. H., and Rose-John, S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med., 183: 1399-1406, 1996.
28. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G. D., Taga, T., and Kishimoto, T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood, 82: 1120-1126, 1993.
29. Baumann, H., Wang, Y., Morella, K. K., Lai, C. F., Dams, H., Hilton, D. J., Hawley, R. G., and Mackiewicz, A. Complex of the soluble IL-11 receptor and IL-11 acts as IL6-type cytokine in hepatic and nonhepatic cells. J. Immunol., 157: 284-290, 1996.
30. Adler, A., Schachter, J., Barenholz, Y., Bar, L. K., Klein, T., Korytnaya, R., Sulkes, A., Michowiz, R., Cohen, Y., and Kedar, I. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects. Cancer Biother., 10: 293-306, 1995.
31. Saito, T., Taga, T., Miki, D., Futatsugi, K., Yawata, H., Kishimoto, T., and Yasukawa, K. Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6 mediated functions. J. Immunol. Methods, 163: 217-223, 1993.
32. Tartour, E., Gey, A., Sastre-Garau, X., Pannetier, C., Mosseri, V., Kourilsky, P., and Fridman, W. H. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res., 54: 6243-6248, 1994.
33. Müllberg, J., Dittrich, E., Graeve, L., Gerhartz, K., Yasukawa, K., Taga, T., Kishimoto, T., Heinrich, P. C., and Rose-John, S. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett., 332: 174-178, 1993.
34. Geisterfer, M., Richards, C. D., and Gauldie, J. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). Cytokine, 7: 503-509, 1995.
35. Saito, M., Yoshida, K., Hibi, M., Taga, T., and Kishimoto, T. Molecular cloning of a murine IL-6 receptor associated signal transducer, gp130, and its regulated expression in vivo. J. Immunol., 148: 4066-4071, 1992.
36. Murakami-Mori, K., Taga, T., Kishimoto, T., and Nakamura, S. The soluble form of the IL-6 receptor (sIL-6Rα) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6Rα-induced AIDS-KS cell growth. Int. Immunol., 8: 595-602, 1996.
37. May, L. T., Patel, K., Garcia, D., Dubuisi, M. I. N., Ferrone, S., Mittelman, A., Mackiewicz, A., and Sehgal, P. B. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood, 84: 1887-1895, 1994.
38. De Benedetti, F., Massa, M., Pignatti, P., Albani, S., Novick, D., and Martini, A. Serum soluble interleukin 6 (IL6) receptor and IL-6/ soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest., 93: 2114-2119, 1995.
39. Cherel, M., Sorel, M., Lebeau, B., Dubois, S., Moreau, J. F., Bataille, R., Minvielle, S., and Jacques, Y. Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. Blood, 86: 2534-2540, 1995.
40. Armstrong, C. A., Murray, N., Kennedy, M., Koppula, S. V., Tara, D., and Ansel, J. C. Melanoma-derived interleukin-6 inhibits in vivo melanoma growth. J. Invest. Dermatol., 102: 278-284, 1994.
41. Lu, C., and Kerbel, R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol., 120: 1281-1288, 1993.
42. Lu, C., Sheehan, C., Rak, J. W., Chambers, C. A., Hozumi, N., and Kerbel, R. S. Endogenous interleukin 6 can function as an in vivo growth factor-stimulatory factor for advanced-stage human melanoma cells. Clin. Cancer Res., 2: 1417-1425, 1996.
43. Paglia, D., Oran, A., Lu, C., Kerbel, R. S., Sauder, D. N., and McKenzie, R. C. Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. J. Interferon Cytokine Res., 15: 455-460, 1995.
44. Matsuda, T., and Hirano, T. Establishment of the ELISA for murine soluble gp130, a signal transducer for the IL-6 family cytokine and its detection in the ascitic fluids of tumor bearing mice. Biochem. Biophys. Res. Commun., 202: 637-642, 1994.
45. Liu, J., Modrell, B., Aruffo, A., Marken, J. S., Taga, T., Yasukawa, K., Murakami, M., Kishimoto, T., and Shoyab, M. Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J. Biol. Chem., 267: 16763-16766, 1992.
46. Wijdenes, J., Heinrich, P. C., Muller-Newen, G., Roche, C., Gu, Z. J., Clement, C., and Klein, B. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur. J. Immunol., 25: 3474-3481, 1995.
47. Chevalier, S., Fourcin, M., Robledo, O., Wijdenes, J., Pouplard-Barthelaix, A., and Gascan, H. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. J. Biol. Chem., 271: 14764-14772, 1996.